Ankyra

Ankyra Therapeutics is focused on developing innovative immunotherapy treatments for cancer that improve both the efficacy and safety of therapeutic cytokines. Their proprietary platform, Anchored Immunotherapy, involves localizing cytokines specifically and persistently when injected into tumor tissue. This creates intense "hotspots" of inflammation, awakening the patient's immune system to attack and destroy cancer cells. Ankyra is currently developing ANK-101, a product candidate based on their Anchored Immunotherapy platform. ANK-101 is being investigated for the treatment of solid tumors and has shown promising results in preclinical studies.

Jobs: